Chuikyo Debate on FY2026 Drug Pricing Reform

• Providers Push to Expand 2% Buffer Zone in Drug Price Revisions as Costs Rise
  November 20, 2025

• Japan Moves to Advance “G1” Price Cuts by 5 Years under Proposed LLP Overhaul
  November 20, 2025

• Chuikyo Split over Higher Copays under LLP Scheme; Payer Push Meets Provider Caution
  November 17, 2025

• Chuikyo Backs Halving Profit Coefficient for Conditionally Approved Regenerative Medicines
  November 13, 2025

• Industry Opposes Deeper CEA Price Cuts for “Cost-Increase” Products
  November 13, 2025

• Tepid Exchanges at Chuikyo over Public-Private Working Group Report
  November 6, 2025

• Japan Mulls Full Overhaul of LLP Rule under FY2026 Drug Pricing Reform
  October 30, 2025

• Exclude High-Price-Gap Products from Unprofitable Drug Re-Pricing: Chuikyo
  October 30, 2025

• FIRM Urges Continued Premiums for Conditionally Approved Regenerative Medicines
  October 30, 2025

• Japan Eyes Review of Generic Price Bands, Brand-Based Revisions for Tier A Products
  October 30, 2025

• No Objections to Expanding Reimbursement Incentives for Biosimilars: Chuikyo
  October 20, 2025

• Payers, Providers Clash over Fate of Fee Premiums for Generic Use
  October 20, 2025

• Japan to Clarify Criteria for Upward Price Adjustments under CEA Scheme
  October 16, 2025

• Deeper CEA Price Cuts Mooted for “Cost Increase” Products: FY2026 Reform Debate
  October 16, 2025

• Chuikyo Urges Stricter Pricing Rules for Conditionally Approved Regenerative Medicines
  October 16, 2025

• Chuikyo Frowns on Industry Calls for Scrapping Huge-Seller Re-Pricing, Spillovers
  October 9, 2025

• Chuikyo Wary of Revising “Zero” Premium Rule for Low Cost Disclosure
  October 9, 2025

• Rift Surfaces over What Constitutes “Objective Review” of CEA
  September 29, 2025

• Pharmacies, Wholesalers Split on Weekend Deliveries at Chuikyo
  September 18, 2025

• Generic Firms Push Reform to Ensure Stability, Wholesalers Seek End to Off-Year Cuts
  September 18, 2025

ページ